24/7 Market News Snapshot 26 March, 2025 – Leap Therapeutics, Inc. Common Stock (NASDAQ:LPTX)

March 26, 2025

DENVER, Colo., 26 March, 2025 (247marketnews.com) – (Nasdaq:LPTX) are discussed in this article.
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology firm focused on developing innovative cancer therapies, is witnessing noteworthy activity in the stock market with its shares currently trading at $0.608, a remarkable 56.70% jump from the previous session’s close of $0.388. This surge is accompanied by an impressive trading volume of 15.86 million shares, indicating robust investor interest as traders seize opportunities within the biotech sector.

Concurrently, Leap Therapeutics has announced significant clinical updates from the DeFianCe study, highlighting the promising efficacy of sirexatamab (DKN-01) in patients with advanced microsatellite stable colorectal cancer (MSS CRC). The updated data reveal that patients exhibiting elevated levels of DKK1, when treated with a combination of sirexatamab, bevacizumab, and chemotherapy, experienced a 32% improvement in overall response rate (ORR) and a progression-free survival (PFS) extended by 3.5 months compared to control subjects. Notably, patients who had not previously received anti-VEGF therapy experienced a 22% increase in ORR and a 2.6-month advantage in PFS.

As of March 12, 2025, 34 patients remain on sirexatamab treatment, contrasting with 24 in the control group, suggesting potential long-term benefits. Dr. Cynthia Sirard, Chief Medical Officer of Leap Therapeutics, emphasized that these new insights solidify their belief in sirexatamab as a viable treatment option for CRC patients with elevated DKK1 levels or those who have not received prior anti-VEGF therapies.

Looking ahead, Leap Therapeutics plans to advance sirexatamab into a Phase 3 registrational trial to further assess its safety and efficacy in the targeted patient population. With approximately 30,000 treated CRC patients in the United States, particularly within the subset possessing high DKK1 levels, there is a significant market opportunity. A conference call is scheduled for today at 8:00 a.m. ET to delve into these impactful findings, marking a crucial step towards enhancing treatment options in the realm of colorectal cancer.

Related news for (LPTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.